BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1743 related articles for article (PubMed ID: 8671425)

  • 1. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
    Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
    Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin.
    Imthurn B; Macas E; Rosselli M; Keller PJ
    Hum Reprod; 1996 Nov; 11(11):2387-91. PubMed ID: 8981116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of highly purified FSH (metrodin-high purity) with pergonal for IVF superovulation.
    Bagratee JS; Lockwood G; López Bernal A; Barlow DH; Ledger WL
    J Assist Reprod Genet; 1998 Feb; 15(2):65-9. PubMed ID: 9513843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization.
    Daya S; Gunby J; Hughes EG; Collins JA; Sagle MA
    Hum Reprod; 1995 Jun; 10(6):1392-6. PubMed ID: 7593503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental protein 14 concentrations in circulation related to hormonal parameters and reproductive outcome in women undergoing IVF/ICSI.
    Westergaard LG; Yding Andersen C; Erb K; Laursen SB; Rasmussen PE; Rex S; Teisner B
    Reprod Biomed Online; 2004 Jan; 8(1):91-8. PubMed ID: 14759294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes.
    Kilani Z; Dakkak A; Ghunaim S; Cognigni GE; Tabarelli C; Parmegiani L; Filicori M
    Hum Reprod; 2003 Jun; 18(6):1194-9. PubMed ID: 12773445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
    Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
    Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of concentration of circulating luteinizing hormone in late-follicle phase on the outcome of in vitro fertilization for normogonadotrophic women].
    Sun H; Hu Y; Wang B; Chen Q; Zhang N; Chen H; Wang J; Xu Z
    Zhonghua Nan Ke Xue; 2004 Dec; 10(12):912-5. PubMed ID: 15638021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective comparative study on IVF outcomes with either purified FSH or human menopausal gonadotrophin in downregulated normogonadotrophic women.
    Ismail AF; Hesham AI; Salah Z; Khaled M; Fouad N; Ashraf N; Hatem S; Hamdi B
    Gynecol Obstet Invest; 2002; 53(4):220-3. PubMed ID: 12186987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.
    Westergaard LG; Laursen SB; Andersen CY
    Hum Reprod; 2000 May; 15(5):1003-8. PubMed ID: 10783342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone.
    Develioglu OH; Cox B; Toner JP; Oehninger S; Muasher SJ
    Hum Reprod; 1999 May; 14(5):1168-74. PubMed ID: 10325255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.